Compugen Ltd. Discloses Novel Troponin Variant for Identification of Cardiac Muscle Injury, Receipt of Patent for the Molecule and Collaboration with Biosite Incorporated
TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:CGEN - News) disclosed today the discovery and experimental verification of CGEN-144, a novel variant of Troponin I biomarker, and the signing of a research and license option agreement with Biosite, Inc. Compugen also announced that a patent for this biomarker has been granted by the US Patent and Trademark Office.